PUREfi Wealth LLC Buys New Position in Novo Nordisk A/S (NYSE:NVO)

PUREfi Wealth LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,953 shares of the company’s stock, valued at approximately $254,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NVO. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the third quarter worth $42,000. Albion Financial Group UT raised its holdings in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Sound Income Strategies LLC raised its holdings in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC bought a new position in Novo Nordisk A/S in the fourth quarter worth $46,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.1 %

NYSE NVO opened at $77.94 on Friday. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15. The stock has a market cap of $349.75 billion, a P/E ratio of 23.69, a P/E/G ratio of 0.96 and a beta of 0.45. The stock’s fifty day moving average price is $89.31 and its 200-day moving average price is $110.18. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on NVO shares. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.